Latest Ignyta Inc. (RXDX) Headlines Ignyta Anno
Post# of 41
Posted On: 03/11/2014 6:16:50 AM
Latest Ignyta Inc. (RXDX) Headlines
Ignyta Announces 2013 Company Highlights and Full Year Financial Results
Business Wire - Fri Feb 28, 3:00PM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013.
Ignyta submits RXDX-101's NDA to FDA, seeking approval in treating metastatic cancer patients
M2 - Fri Feb 28, 3:42AM CST
Biotechnology company Ignyta (OTC BB:RXDX) disclosed on Thursday the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, RXDX-101.
Ignyta Announces Submission of IND for RXDX-101
Business Wire - Thu Feb 27, 8:01AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.
Ignyta to Report 2013 Company Highlights and Financial Results and Host Conference Call on February 28, 2014
Business Wire - Mon Feb 24, 6:00AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its 2013 financial results after the market closes on Friday, February 28, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results, and answer questions.
Ignyta reports preliminary data from RXDX-101 Phase 1 clinical trial at the IASLC 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting
M2 - Fri Feb 21, 4:56AM CST
Biotechnology company Ignyta Inc (OTC BB:RXDX) revealed on Thursday that it has presented preliminary results from its ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101 at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Ignyta Announces Preliminary Data from RXDX-101 Phase 1 Clinical Trial
Business Wire - Thu Feb 20, 4:00PM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. The trial is ongoing, with final results for the Phase 1 portion of the trial expected later this year.
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Business Wire - Wed Feb 19, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Sara Zaknoen, M.D., has been appointed as Chief Medical Officer, assuming full-time responsibilities for the role from James L. Freddo, M.D., who was previously serving as Ignyta's Chief Medical Officer on a consulting basis.
LifeSci Advisors Initiates Coverage of Ignyta, Inc.
Marketwire - Fri Feb 14, 8:00AM CST
LifeSci Advisors, LLC and Ignyta, Inc. (OTCQB: RXDX)
Ignyta Announces Effectiveness of Form S-1 Resale Registration Statement
Business Wire - Wed Feb 12, 6:26AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that on February 11, 2014, the Securities and Exchange Commission declared effective the company's registration statement on Form S-1 relating to resale of up to 9,010,238 shares of Ignyta's common stock, par value $0.00001 per share, by certain selling stockholders. The company registered these shares to satisfy commitments it made in connection with the raising of approximately $54 million in equity financing to certain institutional investors and high net worth individuals.
Ignyta Announces Resignation of Patrick O'Connor
Business Wire - Thu Feb 06, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that as of February 5, 2014, Dr. Patrick O'Connor has resigned as Chief Scientific Officer and SVP, Head of Research of the company in order to focus on his health, thereby ending his previously announced medical leave of absence.
Ignyta to Present at February Investment Conferences
Business Wire - Wed Feb 05, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Jonathan Lim, M.D., chairman and chief executive officer, will make presentations at the following investment conferences:
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Ignyta Receives $10 Million Through Expanded Capital Term Loan from Silicon Valley Bank
Business Wire - Mon Jan 06, 5:59AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Silicon Valley Bank (SVB) has bolstered its support of Ignyta through an expanded $10M capital term loan facility. The new facility replaces the previous $1.5M facility entered into between a wholly-owned subsidiary of Ignyta and SVB in June 2012 and February 2013.
Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target Price
Marketwire - Wed Nov 20, 8:01AM CST
Vista Partners announced today that it has initiated coverage on Targeted Medical Pharma, Inc. (OTCQB: TRGM) ("The Company," or "TRGM"); with a twelve month target price of $2.75. Ross Silver, Principal Analyst at Vista Partners, stated, "TRGM develops and sells a line of patented prescription medical food products that are currently sold in the United States through a network of distributors and directly to physicians who dispense medical foods and other pharmaceutical products through their office practices. With recent reductions in physician reimbursements for medical services by Medicare, workers compensation and private insurance companies, many physicians are actively seeking additional sources of practice revenues." Mr. Silver concludes, "Nestle Health Science, a subsidiary of Nestle, has been actively acquiring medical food companies, one of which was Prometheus Laboratories, a firm specializing in diagnostics and pharmaceuticals in gastrointestinal and oncology. According to an article by Bloomberg, Nestle may have paid 500M Swiss Francs ($550M U.S.) to 1B Swiss Francs ($1.1B U.S.) for Prometheus."
Global Predictive Diagnostics Market Analysis 2013-2018: Increasing Incidence and Prevalence of CDDs is a Major Growth Driver
M2 - Tue Nov 19, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/wjx9v6/predictive#summary) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Major Market Trends, Drivers & Issues 3. Product Overview 4. Recent Industry Activity 5. Focus On Select Players 6. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - - Germany (4) - - The United Kingdom (7) - - Spain (1) - - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/wj...ve#summary
Fish & Richardson's U.S. Supreme Court Mayo Clinic Case Named "2013 Impact Patent Case of the Year" by LMG Life Sciences
PR Newswire - Fri Oct 11, 8:00AM CDT
Fish & Richardson announced today that LMG Life Sciences has named its high profile U.S. Supreme Court win for Mayo Clinic in Mayo Collaborative Servs. v. Prometheus Labs one of two "2013 Impact Patent Cases of the Year." Fish won the unanimous 9-0 decision at the U.S. Supreme Court for long-time client Mayo Clinic in March 2012 after eight years of hard-fought patent litigation with Prometheus Laboratories. The Court ruled in Mayo Clinic's favor that Prometheus' two broad drug monitoring patents were invalid and not patent eligible.
Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin?2 in SITC Guidelines for Treatment of Cutaneous Melanoma
PR Newswire - Thu Oct 10, 8:15AM CDT
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces the inclusion of Proleukin® (aldesleukin for injection) / Interleukin-2 in newly issued guidelines from the Society for Immunotherapy of Cancer (SITC) for the treatment of high risk and advanced- stage cutaneous melanoma. The guidelines, which appear in the August 23rd issue of the journalNature Reviews in Clinical Oncology1, are the first evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with melanoma.
Prometheus Laboratories Appoints Chief Executive Officer
PR Newswire - Thu Sep 19, 8:00AM CDT
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company announced today that Ms. Lisa Miller has been appointed to the position of Chief Executive Officer.
Vital Therapies, Inc. Expands Executive Team
Marketwire Canada - Fri Sep 06, 5:00AM CDT
Vital Therapies(R), Inc. (VTI), a biopharmaceutical company developing a cell-based therapy targeting the treatment of acute liver failure, today announced recent expansion of the company's executive team.
Ignyta Announces 2013 Company Highlights and Full Year Financial Results
Business Wire - Fri Feb 28, 3:00PM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013.
Ignyta submits RXDX-101's NDA to FDA, seeking approval in treating metastatic cancer patients
M2 - Fri Feb 28, 3:42AM CST
Biotechnology company Ignyta (OTC BB:RXDX) disclosed on Thursday the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, RXDX-101.
Ignyta Announces Submission of IND for RXDX-101
Business Wire - Thu Feb 27, 8:01AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.
Ignyta to Report 2013 Company Highlights and Financial Results and Host Conference Call on February 28, 2014
Business Wire - Mon Feb 24, 6:00AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its 2013 financial results after the market closes on Friday, February 28, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results, and answer questions.
Ignyta reports preliminary data from RXDX-101 Phase 1 clinical trial at the IASLC 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting
M2 - Fri Feb 21, 4:56AM CST
Biotechnology company Ignyta Inc (OTC BB:RXDX) revealed on Thursday that it has presented preliminary results from its ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101 at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Ignyta Announces Preliminary Data from RXDX-101 Phase 1 Clinical Trial
Business Wire - Thu Feb 20, 4:00PM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. The trial is ongoing, with final results for the Phase 1 portion of the trial expected later this year.
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Business Wire - Wed Feb 19, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Sara Zaknoen, M.D., has been appointed as Chief Medical Officer, assuming full-time responsibilities for the role from James L. Freddo, M.D., who was previously serving as Ignyta's Chief Medical Officer on a consulting basis.
LifeSci Advisors Initiates Coverage of Ignyta, Inc.
Marketwire - Fri Feb 14, 8:00AM CST
LifeSci Advisors, LLC and Ignyta, Inc. (OTCQB: RXDX)
Ignyta Announces Effectiveness of Form S-1 Resale Registration Statement
Business Wire - Wed Feb 12, 6:26AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that on February 11, 2014, the Securities and Exchange Commission declared effective the company's registration statement on Form S-1 relating to resale of up to 9,010,238 shares of Ignyta's common stock, par value $0.00001 per share, by certain selling stockholders. The company registered these shares to satisfy commitments it made in connection with the raising of approximately $54 million in equity financing to certain institutional investors and high net worth individuals.
Ignyta Announces Resignation of Patrick O'Connor
Business Wire - Thu Feb 06, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that as of February 5, 2014, Dr. Patrick O'Connor has resigned as Chief Scientific Officer and SVP, Head of Research of the company in order to focus on his health, thereby ending his previously announced medical leave of absence.
Ignyta to Present at February Investment Conferences
Business Wire - Wed Feb 05, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Jonathan Lim, M.D., chairman and chief executive officer, will make presentations at the following investment conferences:
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Ignyta Receives $10 Million Through Expanded Capital Term Loan from Silicon Valley Bank
Business Wire - Mon Jan 06, 5:59AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Silicon Valley Bank (SVB) has bolstered its support of Ignyta through an expanded $10M capital term loan facility. The new facility replaces the previous $1.5M facility entered into between a wholly-owned subsidiary of Ignyta and SVB in June 2012 and February 2013.
Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target Price
Marketwire - Wed Nov 20, 8:01AM CST
Vista Partners announced today that it has initiated coverage on Targeted Medical Pharma, Inc. (OTCQB: TRGM) ("The Company," or "TRGM"); with a twelve month target price of $2.75. Ross Silver, Principal Analyst at Vista Partners, stated, "TRGM develops and sells a line of patented prescription medical food products that are currently sold in the United States through a network of distributors and directly to physicians who dispense medical foods and other pharmaceutical products through their office practices. With recent reductions in physician reimbursements for medical services by Medicare, workers compensation and private insurance companies, many physicians are actively seeking additional sources of practice revenues." Mr. Silver concludes, "Nestle Health Science, a subsidiary of Nestle, has been actively acquiring medical food companies, one of which was Prometheus Laboratories, a firm specializing in diagnostics and pharmaceuticals in gastrointestinal and oncology. According to an article by Bloomberg, Nestle may have paid 500M Swiss Francs ($550M U.S.) to 1B Swiss Francs ($1.1B U.S.) for Prometheus."
Global Predictive Diagnostics Market Analysis 2013-2018: Increasing Incidence and Prevalence of CDDs is a Major Growth Driver
M2 - Tue Nov 19, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/wjx9v6/predictive#summary) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Major Market Trends, Drivers & Issues 3. Product Overview 4. Recent Industry Activity 5. Focus On Select Players 6. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - - Germany (4) - - The United Kingdom (7) - - Spain (1) - - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/wj...ve#summary
Fish & Richardson's U.S. Supreme Court Mayo Clinic Case Named "2013 Impact Patent Case of the Year" by LMG Life Sciences
PR Newswire - Fri Oct 11, 8:00AM CDT
Fish & Richardson announced today that LMG Life Sciences has named its high profile U.S. Supreme Court win for Mayo Clinic in Mayo Collaborative Servs. v. Prometheus Labs one of two "2013 Impact Patent Cases of the Year." Fish won the unanimous 9-0 decision at the U.S. Supreme Court for long-time client Mayo Clinic in March 2012 after eight years of hard-fought patent litigation with Prometheus Laboratories. The Court ruled in Mayo Clinic's favor that Prometheus' two broad drug monitoring patents were invalid and not patent eligible.
Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin?2 in SITC Guidelines for Treatment of Cutaneous Melanoma
PR Newswire - Thu Oct 10, 8:15AM CDT
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces the inclusion of Proleukin® (aldesleukin for injection) / Interleukin-2 in newly issued guidelines from the Society for Immunotherapy of Cancer (SITC) for the treatment of high risk and advanced- stage cutaneous melanoma. The guidelines, which appear in the August 23rd issue of the journalNature Reviews in Clinical Oncology1, are the first evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with melanoma.
Prometheus Laboratories Appoints Chief Executive Officer
PR Newswire - Thu Sep 19, 8:00AM CDT
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company announced today that Ms. Lisa Miller has been appointed to the position of Chief Executive Officer.
Vital Therapies, Inc. Expands Executive Team
Marketwire Canada - Fri Sep 06, 5:00AM CDT
Vital Therapies(R), Inc. (VTI), a biopharmaceutical company developing a cell-based therapy targeting the treatment of acute liver failure, today announced recent expansion of the company's executive team.
(0)
(0)Prometheus Biosciences Inc. (RXDX) Stock Research Links
Scroll down for more posts ▼